Nov 04, 2020
Ionis reports third quarter 2020 financial results and recent business achievements
Oct 30, 2020
Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology Product
Oct 22, 2020
Ionis' third novel antisense medicine for ALS, its first designed to treat a broad ALS population, begins clinical trial
Oct 15, 2020
Ionis antisense medicine being evaluated in an investigator-initiated clinical study of COVID-19 patients in Brazil
Oct 13, 2020
Ionis' inhaled antisense medicine demonstrates potential as a novel treatment for cystic fibrosis
Oct 01, 2020
Ionis Chief Scientific Officer Frank Bennett receives Lifetime Achievement Award from Oligonucleotide Therapeutics Society
Sep 30, 2020
Ionis treatment for Alexander disease receives orphan drug designation from U.S. FDA
Sep 03, 2020
Ionis to present at upcoming virtual investor conferences
Sep 02, 2020
New England Journal of Medicine publishes study results evaluating Ionis antisense therapy in treatment of patients with hereditary angioedema
Aug 18, 2020
Akcea and Ionis to Present Phase 2 Results of AKCEA-APOCIII-L(Rx) in Late-Breaking Presentation at ESC Congress 2020
Aug 05, 2020
Ionis reports second quarter 2020 financial results and recent business achievements
Jul 07, 2020
Ionis Pharmaceuticals to hold neurology franchise webcast
Jun 08, 2020
Akcea announces approval for reimbursement of TEGSEDI® (inotersen) in Italy for treatment of hereditary transthyretin amyloidosis with polyneuropathy
Jun 05, 2020
Ionis Pharmaceuticals to present at upcoming virtual investor conferences
May 28, 2020
Ionis Pharmaceuticals to host 2020 virtual annual meeting of stockholders
May 07, 2020
Akcea Expands Leadership Team with Appointment of Carla Poulson as Senior Vice President and Chief Human Resources Officer
May 06, 2020
Ionis reports first quarter 2020 financial results and recent business achievements
May 01, 2020
Ionis Pharmaceuticals to host 2020 virtual annual meeting of stockholders
Apr 22, 2020
Ionis Pharmaceuticals to hold first quarter 2020 financial results webcast
Apr 20, 2020
Ionis and partner announce enrollment completion of global Phase 3 GENERATION HD1 study for Huntington's disease